Dapagliflozin alleviates heart failure with preserved ejection fraction potentially by regulating the AIM2/caspase-1/GSDMD pathway and attenuating pyroptosis
Sailiang Ding, Hao Yang, Ting Lu, Yibin Luo, Liang Xu, Xianghui Zeng · 2026
Read Dapagliflozin alleviates heart failure with preserved ejection fraction potentially by regulating the AIM2/caspase-1/GSDMD pathway and attenuating pyroptosis by Sailiang Ding, Hao Yang, Ting Lu, Yibin Luo, Liang Xu, Xianghui Zeng (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13261332.txt.
Description
Sailiang Ding and colleagues probe how a diabetes drug calms a stiff-heart form of heart failure. In HFpEF the heart still squeezes normally but relaxes badly, and inflammation feeds the decline. Their 2026 mouse study tests whether dapagliflozin works by stopping a fiery cell-death program called pyroptosis.
Treated mice showed eased failure symptoms and far less pyroptosis in heart tissue. A sensor protein, AIM2, ran high in sick hearts and fell under the drug. Dialing AIM2 down or up in cells and animals moved the whole death pathway with it. The authors place the AIM2, caspase-1, and GSDMD chain at the drug's core action.
Catalog record
| CREATOR | Sailiang Ding, Hao Yang, Ting Lu, Yibin Luo, Liang Xu, Xianghui Zeng |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 77 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |